聚乙二醇洛塞那肽注射液联合二甲双胍对初诊肥胖2型糖尿病的疗效及安全性评价

目的 通过观察皮下注射聚乙二醇洛塞那肽注射液联合口服二甲双胍治疗初诊肥胖2型糖尿病患者的疗效,并评价其耐受性和安全性.方法 纳入2019年10月至2020年12月就诊于空军第九八六医院内分泌科初次确诊为肥胖2型糖尿病患者69例.其中男性31例,女性38例,年龄35～65岁,平均(50±13)岁.采用随机数字表法、平行对...

Efficacy and safety of polyethylene glycol loxenatide injection combined with metformin in obese patients with newly diagnosed type 2 diabetes

Objective To investigate the efficacy of subcutaneous polyethylene glycol loxenatide com-bined with metformin in obese patients with newly diagnosed type 2 diabetes,and to preliminary evaluate the tol-erability and safety of the combination therapy.Methods Included in were 69 obese patients with type 2 dia-betes newly diagnosed at Department of Endocrinology,PLA Air Force No.986 Hospital between October 2019 and December 2020.These patients,31 males and 38 females,were 35-65 years old with a mean age of(50±13)years.Using a random number table method and a parallel controlled study design,all patients were divided into:group A(control group,n=34)to receive subcutaneous injection of 0.5 ml saline once weekly and group B(treat-ment group,n=35)to receive subcutaneous injection of 0.5 ml polyethylene glycol loxenatide(200μg)once week-ly.The both groups were given oral metformin(500 mg)thrice daily.The treatment lasted 12 weeks and then the patients were followed up for 12 weeks.The two groups were examined for fasting blood glucose(FBG),2h post-prandial blood glucose(2 h PBG),glycosylated hemoglobin(HbA1c),body weight and body mass index(BMI),in-cidence of hypoglycemia,and adverse reactions at baseline,at 4,8 and 12 weeks of treatment,and at 4 and 12 weeks of follow-up.Results At 12 weeks of treatment,the levels of FBG,2 h PBG,HbA1c,body weight,and BMI decreased in either group compared with baseline(P<0.05),and the reductions from baseline were more sig-nificant in group B,with statistically significant differences(P<0.01).After treatment,the values of FBG,2 h PBG,HbA1c,body weight,and BMI were significantly lower in group B than those in group A,with statistically signifi-cant differences(all P<0.05).In group A,two patients experienced nausea(5.8%);in group B,six patients experi-enced nausea(17.1%),and two reported headache(5.7%).There were no adverse reactions such as hypoglycemia,abnormality in liver orrenal function,and pancreatitis in either group.Conclusion Polyethylene glycol loxenatide injection combined with metformin can effectively reduce blood sugar,glycosylated hemoglobin,body weight and BMI in obese patients newly diagnosed with type 2 diabetic,with acceptable good tolerability and safety that obvi-ously warrants clinical use.